EA201190064A1 - Соединения этанамина и их применение для лечения депрессии - Google Patents

Соединения этанамина и их применение для лечения депрессии

Info

Publication number
EA201190064A1
EA201190064A1 EA201190064A EA201190064A EA201190064A1 EA 201190064 A1 EA201190064 A1 EA 201190064A1 EA 201190064 A EA201190064 A EA 201190064A EA 201190064 A EA201190064 A EA 201190064A EA 201190064 A1 EA201190064 A1 EA 201190064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
treatment
application
ethanamine
compounds
Prior art date
Application number
EA201190064A
Other languages
English (en)
Inventor
Майкл Балестра
Питер Бернштайн
Глен Эрнст
Уильям Фритце
Джон П. Маккаули
Дэвид Наджиель
Лихонг Шень
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201190064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201190064A1 publication Critical patent/EA201190064A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

Настоящее изобретение относится к соединениям этанамина, а именно к 1-(3-фторфенил)-2-метил-2-(пиридин-2-ил)пропан-1-амину и 2-метил-1-фенил-2-(пиридин-2-ил)пропан-1-амину, их энантиомерам и солям и их применению для лечения депрессии.
EA201190064A 2008-12-24 2009-12-22 Соединения этанамина и их применение для лечения депрессии EA201190064A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24
PCT/SE2009/051493 WO2010074647A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Publications (1)

Publication Number Publication Date
EA201190064A1 true EA201190064A1 (ru) 2012-02-28

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190064A EA201190064A1 (ru) 2008-12-24 2009-12-22 Соединения этанамина и их применение для лечения депрессии

Country Status (31)

Country Link
US (4) US8013165B2 (ru)
EP (2) EP2610246A1 (ru)
JP (1) JP5491524B2 (ru)
KR (1) KR20110097996A (ru)
CN (1) CN102333762B (ru)
AR (1) AR074981A1 (ru)
AU (1) AU2009330745B2 (ru)
BR (1) BRPI0923476A2 (ru)
CA (1) CA2748235A1 (ru)
CL (1) CL2011001590A1 (ru)
CO (1) CO6450688A2 (ru)
CR (1) CR20110365A (ru)
CU (1) CU24017B1 (ru)
DO (1) DOP2011000205A (ru)
EA (1) EA201190064A1 (ru)
EC (1) ECSP11011161A (ru)
GT (1) GT201100186A (ru)
HN (1) HN2011001773A (ru)
IL (1) IL213518A0 (ru)
MX (1) MX2011006680A (ru)
NI (1) NI201100131A (ru)
NZ (1) NZ593282A (ru)
PE (1) PE20120249A1 (ru)
SA (1) SA109310013B1 (ru)
SG (2) SG192510A1 (ru)
SV (1) SV2011003962A (ru)
TW (1) TWI442922B (ru)
UA (1) UA106056C2 (ru)
UY (1) UY32360A (ru)
WO (1) WO2010074647A1 (ru)
ZA (1) ZA201105441B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2748235A1 (en) * 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (ru) 1973-05-26 1982-11-30
US5455259A (en) * 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
ES2142320T3 (es) * 1991-10-30 2000-04-16 Astra Ab Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
EP0633879B1 (en) * 1992-04-03 1998-03-11 Astra Aktiebolag Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
JP4008033B2 (ja) * 1996-04-19 2007-11-14 ナームローゼ・フエンノートチヤツプ・オルガノン 置換ベンジルアミン及びうつ病の治療のためのその使用
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) * 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
CA2748235A1 (en) * 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression

Also Published As

Publication number Publication date
US8013165B2 (en) 2011-09-06
DOP2011000205A (es) 2011-07-15
CN102333762A (zh) 2012-01-25
SV2011003962A (es) 2012-01-06
PE20120249A1 (es) 2012-04-19
AR074981A1 (es) 2011-03-02
US20130137731A1 (en) 2013-05-30
KR20110097996A (ko) 2011-08-31
CO6450688A2 (es) 2012-05-31
GT201100186A (es) 2013-10-08
EP2391606A4 (en) 2012-06-13
HN2011001773A (es) 2014-08-18
CU20110141A7 (es) 2012-01-31
TWI442922B (zh) 2014-07-01
BRPI0923476A2 (pt) 2016-01-19
CU24017B1 (es) 2014-07-30
US20120277272A1 (en) 2012-11-01
IL213518A0 (en) 2011-07-31
JP2012513993A (ja) 2012-06-21
NI201100131A (es) 2012-03-19
WO2010074647A1 (en) 2010-07-01
MX2011006680A (es) 2011-07-12
NZ593282A (en) 2013-06-28
JP5491524B2 (ja) 2014-05-14
CR20110365A (es) 2011-08-09
SG192510A1 (en) 2013-08-30
UA106056C2 (ru) 2014-07-25
TW201028149A (en) 2010-08-01
EP2391606A1 (en) 2011-12-07
ECSP11011161A (es) 2011-07-29
EP2610246A1 (en) 2013-07-03
CL2011001590A1 (es) 2012-06-22
ZA201105441B (en) 2012-03-28
CN102333762B (zh) 2014-06-11
US9035065B2 (en) 2015-05-19
SG171928A1 (en) 2011-07-28
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
CA2748235A1 (en) 2010-07-01
AU2009330745A1 (en) 2011-08-04
UY32360A (es) 2010-07-30
AU2009330745B2 (en) 2012-04-05
SA109310013B1 (ar) 2013-07-28

Similar Documents

Publication Publication Date Title
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201190144A1 (ru) Изотиазолилоксифениламидины и их применение в качестве фунгицидов
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201390214A1 (ru) Гетероарилы и их применение
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
UA106875C2 (uk) Тіадіазолілоксифеніламідини та їх застосування як фунгіцидів
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201270149A1 (ru) Ингибиторы bace
EA201001257A1 (ru) Модуляторы ampk (амф-активируемой протеинкиназы)
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения